Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Kinnaird

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
Lancet (London, England)|January 17, 2021
Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasetsFabrizio D'Ascenzo, Ovidio De Filippo, Guglielmo Gallone, et al.
Heart (British Cardiac Society)|July 22, 2018
Association of comorbid burden with clinical outcomes after transcatheter aortic valve implantationRodrigo Bagur, Glen Philip Martin, Luis Nombela-Franco, et al.
Minerva Cardiology and Angiology|June 17, 2021
Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI RegistrySara Al Raisi, Majd Protty, Sergio Raposeiras-Roubín, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|November 1, 2022
Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter RegistryMichele Millesimo, Edoardo Elia, Giorgio Marengo, et al.
European Heart Journal. Acute Cardiovascular Care|October 2, 2018
Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMIFederico Conrotto, Maurizio Bertaina, Sergio Raposeiras-Roubin, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 21, 2019
Correction to: Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI RegistryOvidio De Fillippo, Martina Cortese, Fabrizio D Ascenzo, et al.
Revista Espanola De Cardiologia (English Ed.)|June 30, 2018
Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or PrasugrelSergio Raposeiras-Roubín, Emad Abu-Assi, Fabrizio D'Ascenzo, et al.
European Journal of Preventive Cardiology|March 14, 2019
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registryFabrizio D'Ascenzo, Maurizio Bertaina, Francesco Fioravanti, et al.
Revista Espanola De Cardiologia (English Ed.)|July 22, 2018
Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary SyndromeSergio Raposeiras-Roubín, Berenice Caneiro Queija, Fabrizio D'Ascenzo, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 29, 2019
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI RegistryOvidio De Filippo, Martina Cortese, Fabrizio D Ascenzo, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
Lancet (London, England)|January 17, 2021
Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasetsFabrizio D'Ascenzo, Ovidio De Filippo, Guglielmo Gallone, et al.
Heart (British Cardiac Society)|July 22, 2018
Association of comorbid burden with clinical outcomes after transcatheter aortic valve implantationRodrigo Bagur, Glen Philip Martin, Luis Nombela-Franco, et al.
Minerva Cardiology and Angiology|June 17, 2021
Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI RegistrySara Al Raisi, Majd Protty, Sergio Raposeiras-Roubín, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|November 1, 2022
Antithrombotic Strategy in Secondary Prevention for High-Risk Patients with Previous Acute Coronary Syndrome: Overlap between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter RegistryMichele Millesimo, Edoardo Elia, Giorgio Marengo, et al.
European Heart Journal. Acute Cardiovascular Care|October 2, 2018
Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMIFederico Conrotto, Maurizio Bertaina, Sergio Raposeiras-Roubin, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 21, 2019
Correction to: Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI RegistryOvidio De Fillippo, Martina Cortese, Fabrizio D Ascenzo, et al.
Revista Espanola De Cardiologia (English Ed.)|June 30, 2018
Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or PrasugrelSergio Raposeiras-Roubín, Emad Abu-Assi, Fabrizio D'Ascenzo, et al.
European Journal of Preventive Cardiology|March 14, 2019
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registryFabrizio D'Ascenzo, Maurizio Bertaina, Francesco Fioravanti, et al.
Revista Espanola De Cardiologia (English Ed.)|July 22, 2018
Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary SyndromeSergio Raposeiras-Roubín, Berenice Caneiro Queija, Fabrizio D'Ascenzo, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 29, 2019
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI RegistryOvidio De Filippo, Martina Cortese, Fabrizio D Ascenzo, et al.
Pageof 14